Please login to the form below
eIF4E inhibitor
This page shows the latest eIF4E inhibitor news and features for those working in and with pharma, biotech and healthcare.
Pfizer signs $507m cancer deal with Effector Therapeutics
Despite being highly oncogenic target which has garnered significant interest from the pharma industry, eIF4E has remained an evasive target for researchers. ... Importantly, we believe that this agreement validates Effector’s pursuit of eIF4E, which
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- bluebird bio reveals plans to launch two gene therapies
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Strategic commitment
- Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
- AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug
- NHS England launches hepatitis C screening scheme to reach 2030 elimination goal
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Valneva and Pfizer initiate phase 3 Lyme disease vaccine study
- Medmeme appoints Dr Joseph Laudano to medical affairs role
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Sarepta to submit application for Duchenne muscular dystrophy gene therapy
- Achieving communication excellence by targeting the right channel at the right time
- Successful product commercialisation: what can we learn from the rare disease setting?
PMHub
Cegedim Health Data
Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...
Latest intelligence
- Strategic commitment
- ...
- KOL Ambassador Program & Podcast Creation: A Customer Story
- ...
- Animation: Living With
- The journey from the patient's perspective...
